SIREN : 809899776
KHADER PHARMACIE is a French company founded 11 years ago, specialized in the sector Activités des sociétés holding. Based in BRIVE-LA-GAILLARDE (19100), this company of category PME shows in 2024 a net income positive of 17 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/C | N/C | N/C | N/C | N/C | N/C | N/C | N/C | N/C |
| Net income | 16 876 € | 21 602 € | 10 381 € | 22 413 € | 10 403 € | -1 743 € | 30 201 € | 32 049 € | 17 691 € |
| EBITDA | -7 463 € | -67 329 € | -13 619 € | -1 575 € | -1 445 € | -1 420 € | -1 303 € | -1 285 € | -1 307 € |
| Net margin | N/C | N/C | N/C | N/C | N/C | N/C | N/C | N/C | N/C |
In 2024, KHADER PHARMACIE generates positive net income of 17 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 18 k€ -> 17 k€.
-7 463 €
-7 463 €
16 876 €
The debt ratio (= Financial debt / Equity x 100) stands at 273%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 27%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 91.9 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high.
273.184%
26.784%
91.932
In 2024, the debt ratio of KHADER PHARMACIE (273.18) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of KHADER PHARMACIE (26.8%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of KHADER PHARMACIE (91.93) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 6890.98. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
6890.98
0.0
In 2024, the liquidity ratio of KHADER PHARMACIE (6890.98) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of KHADER PHARMACIE (0.0x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 41 days. Excellent situation: suppliers finance 41 days of the operating cycle (retail model).
0 €
0 j
41 j
0 j
Based on 54 transactions of similar company sales
in 2024,
the value of KHADER PHARMACIE is estimated at
24 638 €
(range 15 713€ - 126 037€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 54 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare KHADER PHARMACIE with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of KHADER PHARMACIE is not publicly disclosed (confidential accounts filed with INPI).
Yes, KHADER PHARMACIE generated a net profit of 17 k€ in 2024.
The headquarters of KHADER PHARMACIE is located in BRIVE-LA-GAILLARDE (19100), in the department Correze.
The tax return of KHADER PHARMACIE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
KHADER PHARMACIE operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.